Patents Assigned to OncoMed Pharmaceuticals, Inc.
-
Publication number: 20120070438Abstract: Methods of inhibiting melanoma tumor growth, methods of treating melanoma and metastatic melanoma, and methods of reducing the frequency of tumor initiating cells (or cancer stem cells) in melanoma tumors are described. The methods described comprise administering a DLL4 antagonist (e.g., an antibody that specifically binds the extracellular domain of human DLL4) to a subject. Related polypeptides and polynucleotides, compositions comprising the DLL4 antagonists, and methods of making the DLL4 antagonists are also described.Type: ApplicationFiled: September 9, 2011Publication date: March 22, 2012Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Timothy C. Hoey, Lucia Beviglia
-
Publication number: 20120027778Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. Screening methods are also provided.Type: ApplicationFiled: April 1, 2011Publication date: February 2, 2012Applicant: OncoMed Pharmaceuticals, Inc.Inventor: Austin L. GURNEY
-
Patent number: 8088617Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.Type: GrantFiled: January 24, 2008Date of Patent: January 3, 2012Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin Gurney, Aaron Sato, Maureen Fitch-Bruhns
-
Publication number: 20110305695Abstract: The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and Ror receptors and their use.Type: ApplicationFiled: January 12, 2011Publication date: December 15, 2011Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Sanjeev H. SATYAL, Satyajit Sujit Kumar Mitra, Austin L. Gurney
-
Publication number: 20110287011Abstract: Disclosed are DDR1 binding agents and methods of using the agents for treating diseases such as cancer. The disclosure provides antibodies that specifically bind to an extracellular domain of DDR1 and modulate DDR1 activity. The disclosure further provides methods of using agents that modulate the activity of DDRI, such as antibodies that specifically bind DDR1, to reduce the tumorigenicity of tumors comprising cancer stem cells by reducing the frequency or number of cancer stem cells in the tumor. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.Type: ApplicationFiled: August 12, 2009Publication date: November 24, 2011Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Edward Thein Htun Van Der Horst, Sanjeev H. Satyal
-
Publication number: 20110287979Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.Type: ApplicationFiled: February 11, 2011Publication date: November 24, 2011Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
-
Publication number: 20110183866Abstract: The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles and signatures associated with solid tumor stem cells, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of solid tumor stem cells. More particularly, the present invention identifies two profiles of cancer stem cells useful for the diagnosis, characterization, and treatment of cancer and cancer metastases. The invention also provides a variety of reagents such as stem cell gene signatures for use in the diagnosis and management of cancer.Type: ApplicationFiled: March 31, 2011Publication date: July 28, 2011Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, ONCOMED PHARMACEUTICALS, INC.Inventors: Michael F. Clarke, Xinhao Wang, John A. Lewicki, Austin L. Gurney
-
Patent number: 7982013Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.Type: GrantFiled: September 28, 2009Date of Patent: July 19, 2011Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
-
Publication number: 20110165162Abstract: Methods of inhibiting tumor growth, methods of treating cancer, and methods of reducing the frequency of cancer stem cells in a tumor are described. Particularly, the methods are directed to tumors or cancers that comprise a K-ras mutation. The methods described comprise administering a DLL4 antagonist (e.g., an antibody that specifically binds the extracellular domain of human DLL4) to a subject. Related polypeptides and polynucleotides, compositions comprising the DLL4 antagonists, and methods of making the DLL4 antagonists are also described.Type: ApplicationFiled: December 1, 2010Publication date: July 7, 2011Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Timothy C. HOEY, Wan-Ching Yen, Marcus M. Fischer
-
Publication number: 20110123532Abstract: The present invention provides methods for making heteromultimeric molecules, such as bispecific antibodies, and compositions comprising said molecules. The method includes introducing mutations in amino acids that are in contact at the interface of two polypeptides, such that the electrostatic interaction between the ion pairs is altered.Type: ApplicationFiled: April 27, 2010Publication date: May 26, 2011Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. GURNEY, Aaron K. Sato
-
Patent number: 7939263Abstract: The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles and signatures associated with solid tumor stem cells, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of solid tumor stem cells. More particularly, the present invention identifies two profiles of cancer stem cells useful for the diagnosis, characterization, and treatment of cancer and cancer metastases. The invention also provides a variety of reagents such as stem cell gene signatures for use in the diagnosis and management of cancer.Type: GrantFiled: July 30, 2009Date of Patent: May 10, 2011Assignees: The Regents of the University of Michigan, OncoMed Pharmaceuticals, Inc.Inventors: Michael F. Clarke, Xinhao Wang, John A. Lewicki, Austin L. Gurney
-
Patent number: 7919092Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.Type: GrantFiled: May 31, 2007Date of Patent: April 5, 2011Assignee: OncoMed Pharmaceuticals, Inc.Inventors: John A. Lewicki, Austin Gurney, Timothy Hoey, Wan-Ching Yen, Sanjeev Satyal
-
Publication number: 20100316637Abstract: An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-DLL4 antibody.Type: ApplicationFiled: May 18, 2010Publication date: December 16, 2010Applicant: ONCOMED PHARMACEUTICALS, INC.Inventors: AUSTIN GURNEY, FUMIKO AXELROD, TIM HOEY, SANJEEV SATYAL
-
Patent number: 7750124Abstract: An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-DLL4 antibody.Type: GrantFiled: September 28, 2007Date of Patent: July 6, 2010Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin Gurney, Fumiko Axelrod, Tim Hoey, Sanjeev Satyal
-
Patent number: 7723477Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.Type: GrantFiled: October 31, 2006Date of Patent: May 25, 2010Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin Gurney, John Lewicki, Sanjeev Satyal, Timothy Hoey
-
Patent number: 7723112Abstract: The present invention relates to compositions and methods for characterizing, treating and diagnosing cancer. In particular, the present invention provides a cancer stem cell profile, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of cancer and in particular the targeting of solid tumor stem cells.Type: GrantFiled: October 31, 2006Date of Patent: May 25, 2010Assignees: The Regents of the University of Michigan, OncoMed Pharmaceuticals, Inc.Inventors: Michael F. Clarke, Tim Hoey, Xinhao Wang, Scott Dylla, Austin Gurney, Piero Dalerba, Mark Prince, Grace Chen